Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations

Medicine, Pathology, Gastroenterology +16

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Jorge Henao‐Mejia, Eran Elinav, Chengcheng Jin et al. · Nature · 2012 · 2.4K citations

Life Sciences, Immunology, Pathology +12

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations

Medicine, Internal Medicine, Pharmacology +14

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†

Luca Miele, Venanzio Valenza, Giuseppe La Torre et al. · Hepatology · 2009 · 1.4K citations · Full text

Life Sciences, Pathobiology, Pathology +17

Intestinal polyposis in mice with a dominant stable mutation of the β‐catenin gene

Naomoto Harada, Yoshitaka Tamai, Brian Sauer et al. · The EMBO Journal · 1999 · 1.2K citations · Full text

Medicine, Genetics, Molecular Genetics +15